tool compound

EPZ020411是一种特异性有效的 PRMT6 抑制剂， IC50 为 10 nM，比作用于 PRMT1 和 PRMT8 的选择性高10倍多。

3F8 是一种具有选择性的 GSK-3β抑制剂，可用作 GSK3 相关疾病的新工具和潜在治疗候选化合物，可用于研究神经系统疾病和癌症。

BRK inhibitor P21d hydrochloride is a highly potent inhibitor of breast tumor kinase (BRK PTK6), displaying an IC50 of 30 nM. Additionally, it effectively suppresses p-SAM68 with an IC50 value of 52 nM. This compound, BRK inhibitor P21d hydrochloride, serves as a valuable tool for evaluating the efficacy of BRK inhibitors in xenograft breast tumor models, enabling the assessment of their in vivo activity.

CC214-1 是一种 mTOR 抑制剂，具有潜在的抗癌活性，抑制蛋白翻译，可诱导自噬 (autophagy)。 CC214-1 是探索 mTOR 激酶生物学的体外工具化合物，可用于研究骨髓瘤。

JAK3- in -11 (Compound 12) 是表现出强效的、无细胞毒性、不可逆、口服活性的JAK3抑制活性，IC50值为1.7 nM，具有出色的选择性(高于其他 JAK3 亚型的588倍)，共价结合到 JAK3 的 ATP-binding pocket。 JAK3-IN-11 强烈抑制 JAK3 依赖的信号转导和T 细胞增殖，是研究自身免疫性疾病的有效工具。

5-bromo-2-(2,6-dioxopiperidin-3-yl)isoindole-1,3-dione (5-bromo-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione) 是一种合成化合物。它已被用作催化剂以及酶动力学研究中的工具；还被用于酶抑制的研究，以及药物受体相互作用的研究。

TDI-10229 是一种口服有效的可溶性腺苷酸环化酶 (sAC, ADCY10) 抑制剂 (IC50 值为 195 nM)。TDI-10229 在生化和细胞分析中都显示出对 sAC 的纳摩尔级抑制，并表现出足以保证其用作体内工具化合物的小鼠药代动力学特性。

5-PT是一种炔基化的5-羟色胺衍生物，可以进行生物正交的点击化学反应（如叠氮-炔烃环加成反应）并在神经科学研究中作为工具化合物或探针，用于追踪与5-PT作用的蛋白质从而探索5-羟色胺在细胞中的作用机制。

RR-11a is a synthetic enzyme Legumain inhibitor.

BI 99179 是一种具有选择性和高效性的 I 型脂肪酸合成酶 (FAS) 抑制剂，是一种靶向 FAS 的工具化合物，可用于研究癌症。

cIAP1 Ligand-Linker Conjugates 11 Hydrochloride is a chemical compound consisting of an IAP ligand that targets the E3 ubiquitin ligase, along with a PROTAC linker. It is primarily utilized in the development of SNIPERs, a molecular tool for targeted protein degradation[1].

N-(Amino-PEG4)-N-Biotin-PEG4-acid is a PEG-based PROTAC linker that incorporates biotin for labeling purposes. This compound serves as a versatile tool in the synthesis of PROTACs[1].

Pomalidomide-amido-C1-Br is a synthesized conjugate consisting of the Pomalidomide-based cereblon ligand and a linker, functioning as an E3 ligase ligand-linker. This compound serves as a tool for designing a B-Raf PROTAC degrader, specifically PROTAC B-Raf degrader 1, which exhibits anti-cancer activity[1].

NEU3-IN-2（compound 963）是一种基于2-脱氧-2,3-二脱氢-N-乙酰神经氨酰（DANA）的NEU3抑制剂，采用C9联苯氨基甲酸酯为结构框架（Ki: 0.12 μM；IC50: 0.31 μM）。作为人类神经氨酸酶NEU的一种，拥有四种同工酶，NEU3-IN-2主要用于研究NEU3同工酶的功能。此外，其衍生的酰胺和三唑接头类似物对NEU1和NEU4同工酶表现出较好的选择性。

AGH-192, 高效且具化合物特性的激动剂，可能成为研究5-HT7受体功能的理想工具化合物。此外，AGH-192在小鼠神经病理性疼痛模型中观察到的镇痛效果表明，它也有潜力作为一种止痛药。

DL5050是一种针对人类持续性安卓斯坦受体（hCAR）的选择性激动剂。该化合物在对hCAR的亲和力和选择性方面展现出卓越的效能，相较于人类孕烷X受体（hPXR），DL5050更倾向于诱导CYP2B6（hCAR的靶标）而非CYP3A4（hPXR的靶标）在mRNA和蛋白质水平上的表达。作为选择性hCAR激动剂，DL5050不仅是研究hCAR生物学功能的重要工具分子，同时也可能成为开发治疗性应用中hCAR激动剂的新先导化合物。

PAG 4'-piperazine-4-methylpiperidine 是一种用于 PROTAC 研究和开发的功能化 cereblon 配体。包含一个 E3 ligase ligand 和一个末端哌啶，以进一步化学合成生成具有刚性连接子的 Protein Degraders。它是 PROTAC R&D 的一系列功能化工具分子的一部分。

CRHR1 antagonist 1 (compound 10a) 是一种非肽类CRHR1拮抗剂，用于精神疾病研究。

PKN3-IN-1 (compound 16) 抑制 PKN3 (丝氨酸 苏氨酸蛋白激酶 3) 和 GAK (细胞周期蛋白 G 相关激酶)，其 IC50 为 0.014 μM，Ki 为 0.0044 μM。PKN3-IN-1 作为研究 PKN3 在胰腺癌、前列腺癌以及 T 细胞急性淋巴细胞白血病中的生物学功能的潜在工具化合物。

CB2R激动剂, 其化学式为C25H28N6O3S，分子量为508.6 g mol。作为一种高效且具有选择性的CB2R激动剂，该化合物表现出在医疗研究中应用的潜力。其结构包含吡咯并[2,3-b]吡啶-3-胺环，与CB2受体的结合力强。在体外试验中，这种化合物的EC50值为22 nM，体现了其高度选择性。

QAQ dichloride is a photoswitchable compound that blocks voltage-gated Na v and K v channels. Its channel-blocking activity is observed in the trans form of the azobenzene photoswitch, while the cis form does not exhibit this effect. This compound is membrane-impermeant and selectively enters pain-sensing neurons expressing endogenous import channels. QAQ dichloride functions as a light-sensitive analgesic and provides a valuable tool for investigating signaling mechanisms involved in acute and chronic pain [1] [2].

Av-105 is the precursor of florbetapir (18F). It is a radiopharmaceutical compound scanned by pet, which can be used as a diagnostic tool for Alzheimer's disease.

(±)14(15)-EE-8(Z)-E is a potent vasodilator in bovine coronary arteries. The synthesis of this analog involves the formation of the epoxide at the 14,15-double bond, however, epoxidation can also occur at the 8,9-double bond. (±)8(9)-EE-14(Z)-E is a minor product from the synthesis of (±)14(15)-EE-8(Z)-E. This compound has not been reported in the literature, and its biological activity is not known. It may serve as a tool to verify that the parent compound, (±)14(15)-EE-8(Z)-E, is pure and does not contain the 8,9-epoxy regioisomer.

12(S)-HETE is a product of arachidonic acid metabolism through the 12-lipoxygenase pathway. It is primarily found in platelets, leukocytes, and to a lesser extent in smooth muscle cells. It enhances tumor cell adhesion to endothelial cells, fibronectin, and the subendothelial matrix. tetranor-12(S)-HETE is the major β-oxidation product resulting from peroxisomal metabolism of 12(S)-HETE in numerous tissues, and Lewis lung carcinoma cells. No biological function has yet been determined for tetranor-12(S)-HETE. Some data indicate it may play a role in controlling the inflammatory response in injured corneas. In some diseases (e.g., Zellweger's Syndrome) peroxisomal abnormalities result in the inability of cells to metabolize 12(S)-HETE, which may be responsible for symptoms of the disease. The tetranor derivative of 12(S)-HETE is available as a research tool for the elucidation of the metabolic fate of its parent compound.